Imipramine: a model substance in pharmacokinetic research
by
Gram LF.
Department of Clinical Pharmacology,
Odense University.
Acta Psychiatr Scand Suppl. 1988;345:81-4

ABSTRACT

The pharmacokinetics of imipramine have been studied over a period of 20 years. Imipramine is rapidly and almost completely metabolized with the formation of desipramine (desmethylation), 2-hydroxy metabolites and subsequent glucoronide coupling. Imipramine has a high clearance (0.8-1.5 l/min) and a corresponding high first pass elimination (30-70%). Volume of distribution is high (650-1100 1) and half-lives accordingly of medium length (6-12 h). The 2-hydroxylation which is the most important step of elimination is mediated via microsomal cytochrome P450 isozyme that exhibit monogenetic polymorphism such that 5-10% of the population have a severely reduced clearance. Co-administration of neuroleptics may also considerably impair the 2-hydroxylation. Steady-state levels of imipramine and desipramine varies considerably among individuals mainly due to variations in metabolism, but also to a smaller extent due to variations in binding to plasma proteins. The variations in steady-state concentrations appear to have clear implication for the clinical effects of imipramine.

Imipramine
Desipramine
TCAs v SSRIs
Antidepressants
Retarded depression
Selectivity or multiplicity?
Imipramine and enkephalin
Imipramine and depression
Noradrenaline and dopamine
Imipramine and dopamine d1
Imipramine v DL-phenylalanine
Zinc, imipramine and depression
Imipramine (Tofranil) restores appetitive behavior

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family